Case Western Reserve University School of Medicine, Cleveland, OH, USA.
J Vasc Interv Radiol. 2011 Dec;22(12):1697-705. doi: 10.1016/j.jvir.2011.08.013. Epub 2011 Oct 8.
To compare retrospectively the safety and efficacy of yttrium-90 ((90)Y) radioembolization with the safety and efficacy of chemoembolization in patients with unresectable hepatocellular carcinoma (HCC).
Survival and complication rates were evaluated for patients with HCC who underwent chemoembolization or radioembolization at a single institution between August 2007 and April 2010. Complications were graded according to a standardized grading system for embolization procedures. Survival was determined via the Kaplan-Meier method, and multivariable analysis for factors affecting survival was performed.
This study included 73 patients with HCC who underwent index embolization with radioembolization (n = 38; 52.1%) or chemoembolization (n = 35; 47.9%). The two patient populations were similar in terms of demographics, etiology of cirrhosis, functional status, tumor characteristics, Child-Pugh class, previous liver-directed therapy, and number of patients with bilirubin > 2.0 mg/dL. There was no significant difference in survival between the radioembolization (median 8.0 months) and chemoembolization (median 10.3 months) cohorts (P = .33). Postembolization syndrome was significantly more severe in patients who underwent chemoembolization, which led to increased total hospitalization rates in these patients. The rates of other complications and rehospitalization were similar between groups. Increased age, Child-Pugh class B, hepatitis seropositivity, bilobar tumor distribution, tumor vascular invasion, and presence of extrahepatic metastases were associated with reduced patient survival.
Patients treated with radioembolization did not show a survival advantage over patients treated with chemoembolization. However, patients who underwent chemoembolization had significantly higher rates of hospitalization as a result of postembolization syndrome.
回顾性比较钇-90 ((90)Y) 放射性栓塞与化疗栓塞治疗不可切除肝细胞癌 (HCC) 的安全性和疗效。
在 2007 年 8 月至 2010 年 4 月期间,对在一家机构接受化疗栓塞或放射性栓塞治疗的 HCC 患者的生存和并发症发生率进行评估。根据栓塞程序的标准化分级系统对并发症进行分级。通过 Kaplan-Meier 方法确定生存情况,并对影响生存的因素进行多变量分析。
本研究共纳入 73 例接受指数栓塞治疗的 HCC 患者,其中接受放射性栓塞 (n = 38;52.1%) 或化疗栓塞 (n = 35;47.9%)。两组患者在人口统计学、肝硬化病因、功能状态、肿瘤特征、Child-Pugh 分级、既往肝定向治疗以及胆红素 > 2.0mg/dL 的患者人数等方面均相似。放射性栓塞组 (中位生存时间 8.0 个月) 和化疗栓塞组 (中位生存时间 10.3 个月) 的生存情况无显著差异 (P =.33)。化疗栓塞后综合征在接受化疗栓塞的患者中更为严重,导致这些患者的总住院率增加。两组间其他并发症和再住院率相似。年龄增加、Child-Pugh 分级 B、肝炎血清阳性、肿瘤双叶分布、肿瘤血管侵犯和肝外转移存在与患者生存时间缩短相关。
接受放射性栓塞治疗的患者未显示出比接受化疗栓塞治疗的患者具有生存优势。然而,接受化疗栓塞治疗的患者由于栓塞后综合征导致住院率显著升高。